Answers are grounded in this paper and cite their sources.
BACKGROUND AND PURPOSE: Nonsteroidal anti-inflammatory drugs (NSAIDs) are a leading cause of drug hypersensitivity reactions (HRs), but genetic determinants of individual susceptibility remain unclear. Here, we identified genetic variants in redox- and immune-related pathways associated with cross-reactive NSAID hypersensitivity (CR-NSAID) and single-NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA) and to characterize their functional relevance. EXPERIMENTAL APPROACH: A multicentre prospective case-control study was conducted in Spanish individuals of European ancestry, including patients with confirmed NSAID hypersensitivity and NSAID-tolerant individuals. Single nucleotide variants (SNVs) in redox- and immune-related genes were genotyped using a two-stage discovery and independent replication design. SNVs showing significant associations were functionally evaluated by measuring serum glutathione S-transferase (GST), superoxide dismutase (SOD) and aldo-keto reductase (AKR) activities according to genotype. KEY RESULTS: GSTM5 rs11101989 and GSTZ1 haplotype (rs1046428, rs7975, rs7972) associated with increased susceptibility to CR-NSAID. Functional analyses demonstrated that carriers of the GSTM5 rs11101989 CC genotype had significantly reduced total serum GST activity. In SNIUAA, SOD1 variants (rs2070424 and rs2833483) associated with increased susceptibility and reduced serum SOD activity. Additionally, AKR1C3 rs34186955 increased susceptibility, whereas AKR1C3 rs12529 and IL4R rs1805016 associated with decreased susceptibility. Integration of genetic and functional data supported involvement of redox-related pathways in distinct NSAID hypersensitivity phenotypes and identified GSTM5 and SOD1 variants as candidate genetic susceptibility markers. CONCLUSIONS AND IMPLICATIONS: Genetic variability in redox-related and immune-regulatory pathways contributed to susceptibility to cross-reactive and selective NSAID hypersensitivity. These findings support further validation of biomarker-based strategies for personalized risk assessment and safer NSAID prescribing. Further validation in independent populations is required.
No takes yet. Share an insight, caveat, or question.
García-Menaya et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: